Marla Salmon - Grifols SA Independent Director
GRFS Stock | USD 6.39 0.09 1.39% |
Director
Ms. Marla Elizabeth Salmon serves as Independent Director of Grifols, S.A. since 2014. She is Professor of Nursing and Public Health at the University of Washington, as well as Senior Visiting Fellow of Public Affairs. Her career has focused on health policy and capacity building in both global and US contexts, working with governments, international agencies and other health related entities. She holds two honorary doctoral degrees recognizing her national and international service and is a member of the Institute of Medicine. Her board service includes IES Abroad, Inc. the Robert Wood Johnson Foundation, and the National Center for Healthcare Leadership. Her advisory roles include the White House Task Force on Health Care Reform, the World Bank, the World Health Organization Global Advisory Group on Nursing and Midwifery, and the National Institutes of Health National Advisory Committee for the Institute of Nursing Research. since 2014.
Tenure | 10 years |
Address | Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 |
Phone | 34 935 712 200 |
Web | https://www.grifols.com |
Grifols SA Management Efficiency
The company has return on total asset (ROA) of 0.0214 % which means that it generated a profit of $0.0214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.022 %, meaning that it created $0.022 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0 in 2024. Return On Capital Employed is likely to drop to 0.04 in 2024. At this time, Grifols SA's Asset Turnover is comparatively stable compared to the past year.Similar Executives
Showing other executives | DIRECTOR Age | ||
Melanie Lee | Sanofi ADR | 59 | |
Manvinder Banga | GlaxoSmithKline PLC ADR | 62 | |
Togo West | Bristol Myers Squibb | 72 | |
Emmanuel Babeau | Sanofi ADR | 51 | |
Judith Pelham | Amgen Inc | 69 | |
Uwe Bicker | Sanofi ADR | 69 | |
Philip Broadley | AstraZeneca PLC ADR | 52 | |
Frans Houten | Novartis AG ADR | 61 | |
Carla Hills | Gilead Sciences | 80 | |
Rebecca Henderson | Amgen Inc | 57 | |
Peter Voser | Roche Holding Ltd | 59 | |
Nancy Leaming | Biogen Inc | 70 | |
Theodore Samuels | Bristol Myers Squibb | 66 | |
Sanders Williams | Amgen Inc | 69 | |
William Hawkins | Biogen Inc | 64 | |
Dinesh Paliwal | Bristol Myers Squibb | 63 | |
Harish Manwani | Gilead Sciences | 64 | |
Marvinder Banga | GlaxoSmithKline PLC ADR | 66 | |
Tim JacksonSmith | AstraZeneca PLC ADR | N/A | |
Richard Whitley | Gilead Sciences | 72 | |
John Chiminski | Biogen Inc | 53 |
Management Performance
Return On Equity | 0.022 | ||||
Return On Asset | 0.0214 |
Grifols SA ADR Leadership Team
Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Antonio Pares, Director of Planning and Control | ||
Alberto Roura, President Division | ||
Carsten Schroeder, President Of The Diagnostic Division | ||
Albert Roura, CEO of Laboratorios Grifols SA | ||
Lafmin Morgan, President Of The Bioscience And Hospital Division | ||
Juan Roura, Vice President of Production, Executive Director | ||
Eva Tubau, Chief Scientific Officer | ||
Anna Lluch, Independent Director | ||
Carlos Fernandez, Deputy Industrial Vice President | ||
Jose Gras, Director, Representative of Thorthol Holdings BV | ||
Maria Llano, Chief Officer | ||
Edgar Jannotta, Independent Director | ||
Vicente Torre, Chief Officer | ||
Nacho Abia, CEO Director | ||
Mateo Humbert, Director of Human Resources | ||
Montserrat Calvo, Chief Administrative Officer, Controller | ||
Montserrat Llamas, Chief Officer | ||
Ramon Roca, Vice-President of Marketing and Sales and Executive Director | ||
Vctor Deu, CoCEO Director | ||
David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries | ||
Victor Deu, Co-CEO, Executive Director | ||
Luis Bobadilla, Independent Director | ||
Inigo Mardones, Director | ||
Thomas Glanzmann, Executive Chairman | ||
Carina Lazaro, Independent Director | ||
Joel Abelson, President of North America Commercial Division of Grifols Inc | ||
Steven Mayer, Director | ||
Javier Ribes, CEO of Instituto Grifols SA | ||
Alfredo Guerra, CFO and Corporate VP | ||
Raimon Roura, Non-Member Secretary of the Board | ||
Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee | ||
Brett Ingersoll, Director | ||
Shinji Wada, President of Plasma Centers of Grifols Inc | ||
Tomas Gelabert, Director | ||
Nuria Lapea, Risk Treasury | ||
Sergio Adell, President Support | ||
M Tubau, Corporate Affairs | ||
Steven JD, Ex Chairman | ||
Marla Salmon, Independent Director | ||
Nuria Barnes, Non-Member Assistant Secretary of the Board | ||
Gregory Rich, President of Grifols Inc and Subsidiaries in the US | ||
Belen Morenes, Independent Director | ||
Nuria Lapena, Director of Shareholder and Investor Relations |
Grifols Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.022 | ||||
Return On Asset | 0.0214 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 16.55 B | ||||
Shares Outstanding | 679.09 M | ||||
Shares Owned By Institutions | 49.96 % | ||||
Number Of Shares Shorted | 5.97 M | ||||
Price To Earning | 14.34 X | ||||
Price To Book | 0.71 X |
Grifols SA Investors Sentiment
The influence of Grifols SA's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Grifols. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Grifols SA's public news can be used to forecast risks associated with an investment in Grifols. The trend in average sentiment can be used to explain how an investor holding Grifols can time the market purely based on public headlines and social activities around Grifols SA ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Grifols SA's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Grifols SA's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Grifols SA's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Grifols SA.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Grifols SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Grifols SA's short interest history, or implied volatility extrapolated from Grifols SA options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grifols SA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Grifols SA ADR information on this page should be used as a complementary analysis to other Grifols SA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Grifols Stock analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Grifols SA's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grifols SA. If investors know Grifols will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grifols SA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.787 | Earnings Share 0.1 | Revenue Per Share 4.849 | Quarterly Revenue Growth 0.033 | Return On Assets 0.0214 |
The market value of Grifols SA ADR is measured differently than its book value, which is the value of Grifols that is recorded on the company's balance sheet. Investors also form their own opinion of Grifols SA's value that differs from its market value or its book value, called intrinsic value, which is Grifols SA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grifols SA's market value can be influenced by many factors that don't directly affect Grifols SA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grifols SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Grifols SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grifols SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.